期刊文献+

辛伐他汀对急性冠状动脉综合征的调脂及抗炎作用

下载PDF
导出
摘要 目的观察辛伐他汀对急性冠状动脉综合征的调脂及抗炎作用。方法随机将64例住院的急性冠状动脉综合征患者分为治疗组(n=32,辛伐他汀20mg,每晚1次口服)和对照组(n=32),疗程3个月,于治疗前后分别检测患者血清hs-CRP和血脂的水平进行对比,并观察比较两组患者6个月内死亡率和心血管事件发生率。结果治疗前两组血脂和hs-CRP水平差异无显著性(P>0.05)。治疗组治疗后较治疗前TC,TG,LDL-C,hs-CRP水平明显下降(P<0.01),对照组治疗前后血脂各项及hs-CRP差异无显著性(P>0.05)。治疗后两组间比较,治疗组较对照组TC,TG,LDL-C,hs-CRP水平明显下降(P<0.05)。治疗组较对照组6个月内死亡率和心血管事件发生率明显低(P<0.01),治疗中无严重药物不良反应发生。结论辛伐他汀具有明显的降脂及抗炎作用,可改善急性冠状动脉综合征患者的预后,安全可靠。
机构地区 日照市中医医院
出处 《潍坊医学院学报》 2008年第5期467-468,共2页 Acta Academiae Medicinae Weifang
  • 相关文献

参考文献6

  • 1Braunwald E, Antman EM, Beaslcy JW, et al. AAC/AHA Guidelines for the managent of patients with unstable angina and non-st-segment elevation myocardial infarction A report of American collage of cardiology/American hcart association task force or practicc guidelincs[ J]. J Am Coll Cardiol,2000 ,36( 3 ) :970.
  • 2徐叔云.临床药理学[M].第3版.北京:人民卫生出版社.2006.433-434
  • 3王卫明,单其俊,曹克将.C反应蛋白的研究进展[J].心血管病学进展,2005,26(1):73-75. 被引量:52
  • 4Gomes MC. C-reactive protein : a new golden marker of caidiovascular risk[J]. Rev Port Cardiol,2002,21 (10) :1329 - 1346.
  • 5Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease, application to clinical and public health practice, a statement for health care professionals from the centers for disease control and prevention and the American Heart Association [ J ]. Circulation,2003,107 (4) :499.
  • 6秦晋梅,李建军.他汀类药物的抗炎作用[J].中国动脉硬化杂志,2004,12(3):363-366. 被引量:42

二级参考文献72

  • 1Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels.The Prospective Pravastatin Pooling project.Eur Heart J, 2002, 23 (3):207-215
  • 2Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994, 344:1 383-389
  • 3Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.J Am Med Assoc, 1998, 279 (20):1 615-622
  • 4Plutzky J, Ridker PM.Statins for Stroke:The Second Story? Circulation, 2002, 103 (3):348-350
  • 5Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al.Effect of pravastatin on outcomes after cardiac transplantation.N Engl J Med, 1995, 333 (10):621-627
  • 6Wenke K, Meiser B, Thiery J, Nagel D, Scheidt WV, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation.Circulation, 1997, 96 (5):1 398-402
  • 7Strandberg TE, Vanhanen H, Tikkanen MJ.Effect of statins on C-reactive protein with coronary artery disease.Lancet, 1999, 353(9147):118-119
  • 8Rider PM, Rifai N, Pfeffer M, Sacks F, Braunwald E.For the cholesterol and recurrent event (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation, 1999, 100 (3):230-235
  • 9Albert MA, Staggers J, Chew P, Rider PM.The pravastatin inflammation CRP evaluation (PRINCE):rationale and design.Am Heart J, 2001, 141 (6):893-898
  • 10Albert MA, Danielson E, Rifai N, Ridker PM.Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation / CRP Evaluation (PRINCE):A randomize trial and cohort study.J Am Med Assoc, 2001, 286 (1):64-70

共引文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部